Wendy Bernhard1, Kris Barreto1, Ayman El-Sayed1, Carolina Gonzalez1, Raja Solomon Viswas2, Darien Toledo3, Angel Casaco3, John DeCoteau1, Humphrey Fonge4,5, Clarence Ronald Geyer6. 1. Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. 2. Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. 3. Center of Molecular Immunology, Havana, Cuba. 4. Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. humphrey.fonge@usask.ca. 5. Department of Medical Imaging, Royal University Hospital, Saskatoon, SK, Canada. humphrey.fonge@usask.ca. 6. Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. ron.geyer@usask.ca.
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) is a target for cancer therapy as it is overexpressed in a wide variety of cancers. Therapeutic antibodies that bind EGFR are being evaluated in clinical trials as imaging agents for positron emission tomography and image-guided surgery. However, some of these antibodies have safety concerns such as infusion reactions, limiting their use in imaging applications. Nimotuzumab is a therapeutic monoclonal antibody that is specific for EGFR and has been used as a therapy in a number of countries. METHODS: Formulation of IRDye800CW-nimotuzumab for a clinical trial application was prepared. The physical, chemical, and pharmaceutical properties were tested to develop the specifications to determine stability of the product. The acute and delayed toxicities were tested and IRDye800CW-nimotuzumab was determined to be non-toxic. Non-compartmental pharmacokinetics analysis was used to determine the half-life of IRDye800CW-nimotuzumab. RESULTS: IRDye800CW-nimotuzumab was determined to be non-toxic from the acute and delayed toxicity study. The half-life of IRDye800CW-nimotuzumab was determined to be 38 ± 1.5 h. A bi-exponential analysis was also used which gave a t1/2 alpha of 1.5 h and t1/2 beta of 40.8 h. CONCLUSIONS: Here, we show preclinical studies demonstrating that nimotuzumab conjugated to IRDye800CW is safe and does not exhibit toxicities commonly associated with EGFR targeting antibodies.
BACKGROUND:Epidermal growth factor receptor (EGFR) is a target for cancer therapy as it is overexpressed in a wide variety of cancers. Therapeutic antibodies that bind EGFR are being evaluated in clinical trials as imaging agents for positron emission tomography and image-guided surgery. However, some of these antibodies have safety concerns such as infusion reactions, limiting their use in imaging applications. Nimotuzumab is a therapeutic monoclonal antibody that is specific for EGFR and has been used as a therapy in a number of countries. METHODS: Formulation of IRDye800CW-nimotuzumab for a clinical trial application was prepared. The physical, chemical, and pharmaceutical properties were tested to develop the specifications to determine stability of the product. The acute and delayed toxicities were tested and IRDye800CW-nimotuzumab was determined to be non-toxic. Non-compartmental pharmacokinetics analysis was used to determine the half-life of IRDye800CW-nimotuzumab. RESULTS:IRDye800CW-nimotuzumab was determined to be non-toxic from the acute and delayed toxicity study. The half-life of IRDye800CW-nimotuzumab was determined to be 38 ± 1.5 h. A bi-exponential analysis was also used which gave a t1/2 alpha of 1.5 h and t1/2 beta of 40.8 h. CONCLUSIONS: Here, we show preclinical studies demonstrating that nimotuzumab conjugated to IRDye800CW is safe and does not exhibit toxicities commonly associated with EGFR targeting antibodies.
Authors: Eben L Rosenthal; Jason M Warram; Esther de Boer; Thomas K Chung; Melissa L Korb; Margie Brandwein-Gensler; Theresa V Strong; Cecelia E Schmalbach; Anthony B Morlandt; Garima Agarwal; Yolanda E Hartman; William R Carroll; Joshua S Richman; Lisa K Clemons; Lisle M Nabell; Kurt R Zinn Journal: Clin Cancer Res Date: 2015-04-22 Impact factor: 12.531
Authors: Kiranya E Tipirneni; Jason M Warram; Lindsay S Moore; Andrew C Prince; Esther de Boer; Aditi H Jani; Irene L Wapnir; Joseph C Liao; Michael Bouvet; Nicole K Behnke; Mary T Hawn; George A Poultsides; Alexander L Vahrmeijer; William R Carroll; Kurt R Zinn; Eben Rosenthal Journal: Ann Surg Date: 2017-07 Impact factor: 12.969
Authors: Willemieke S Tummers; Sarah E Miller; Nutte T Teraphongphom; Adam Gomez; Idan Steinberg; David M Huland; Steve Hong; Sri-Rajasekhar Kothapalli; Alifia Hasan; Robert Ertsey; Bert A Bonsing; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; Teri A Longacre; George A Fisher; Sanjiv S Gambhir; George A Poultsides; Eben L Rosenthal Journal: Ann Surg Oncol Date: 2018-04-17 Impact factor: 5.344
Authors: Sarah E Miller; Willemieke S Tummers; Nutte Teraphongphom; Nynke S van den Berg; Alifia Hasan; Robert D Ertsey; Seema Nagpal; Lawrence D Recht; Edward D Plowey; Hannes Vogel; Griffith R Harsh; Gerald A Grant; Gordon H Li; Eben L Rosenthal Journal: J Neurooncol Date: 2018-04-06 Impact factor: 4.130
Authors: Marlène C Hekman; Mark Rijpkema; Constantijn H Muselaers; Egbert Oosterwijk; Christina A Hulsbergen-Van de Kaa; Otto C Boerman; Wim J Oyen; Johan F Langenhuijsen; Peter F Mulders Journal: Theranostics Date: 2018-03-08 Impact factor: 11.556